Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Biomunex Pharmaceuticals

Biomunex Pharmaceuticals
2014 FOUNDED
PRIVATE STATUS
Seed LATEST DEAL TYPE
3 INVESTORS
Description

Developer of immunotherapies through a bispecific antibody intended to developing therapeutics in the area of immuno-oncology. The company's platform offers to develop drug candidates with high anti-tumor potential, superior manufacturability and optimal drug-like properties, enabling biotechnology companies to format antibodies from any pair of monospecific monoclonal antibodies as building blocks, in a timely and cost-effective manner.

Ownership Status
Privately Held (backing)
Financing Status
Accelerator/Incubator Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Primary Office
  • 14 avenue d'Eylau
  • 75116 Paris
  • France
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Biomunex Pharmaceuticals’s full profile, request a free trial.

Biomunex Pharmaceuticals Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Seed Round Completed Generating Revenue
3. Accelerator/Incubator Completed Startup
2. Grant 01-Jan-2016 Completed Startup
1. Grant 01-Jan-2014 Completed Startup
To view this company’s complete deal history including valuation and funding, request access »

Biomunex Pharmaceuticals Investors (3)

Investor Name Investor Type Holding Investor Since Participating Rounds Board
Seat
Contact
Info
L'Agence Nationale de la Recherche Government 000 0000 000000 0
Bpifrance Sovereign Wealth Fund 000 0000 000000 0
Agoranov Accelerator/Incubator 000 0000 000000 0

Biomunex Pharmaceuticals Executive Team (4)

Name Title Board
Seat
Contact
Info
Pierre-Emmanuel Gerard Co-Founder & Chief Executive Officer
Eugene Zhukovsky Ph.D Chief Scientific Officer
Jean-Pierre Mach Co-Founder

1 Former Executive

You’re viewing 3 of 4 executives. Get the full list »